Advances in Tuberculosis: Comprehensive Insights and Management Strategies
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Infectious Diseases".
Deadline for manuscript submissions: 20 July 2025 | Viewed by 7
Special Issue Editor
Special Issue Information
Dear Colleagues,
Tuberculosis (TB), the leading cause of death from a curable infectious disease, remains a significant global health challenge. In 2022, 10.6 million people were diagnosed with TB, and 1.6 million TB-related deaths were reported. The COVID-19 pandemic has disrupted TB control programs, reversing recent progress. However, significant scientific breakthroughs in TB prevention, screening, diagnostics, and treatment have emerged in the past decade, offering hope for better control and management.
Recent advances include the use of highly sensitive diagnostic tools like the Xpert MTB/RIF Ultra, capable of the early detection of TB. Shorter, all-oral treatment regimens for drug-susceptible (DS-TB) and drug-resistant TB (DR-TB), endorsed by the WHO, represent significant progress. Understanding the genetic and molecular mechanisms of both the host and Mycobacteria is crucial for advancing TB management strategies.
This Special Issue explores comprehensive strategies for managing TB, including both pulmonary and extra-pulmonary forms. Key topics include innovative TB screening, prevention methods, and rapid diagnostics. This Special Issue also covers treatment regimens for DS-TB and DR-TB and the management of co-infections such as HIV, Hepatitis B and C, and co-morbidities like diabetes.
This Special Issue will our enhance understanding of and improve clinical practice by providing comprehensive insights into TB control and management, spanning innovative screening and diagnostic methods, advanced treatment protocols, and prevention strategies.
Dr. Aliaksandr Skrahin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary and extra-pulmonary tuberculosis (TB)
- TB epidemiology
- TB screening, TB prevention
- TB diagnostics
- TB treatment
- TB co-infections (e.g., HIV, Hepatitis B and C)
- TB co-morbidities (e.g., diabetes)
- host and Mycobacteria genetic
- molecular mechanisms and genotype/phenotype correlations
